Summary outcomes for children receiving hydroxyurea for sickle cell disease
| Outcome | Effect |
|---|---|
| Blood markers | |
| Haemoglobin level | Not significantly different |
| Percentage of fetal haemoglobin | Increased (very low quality evidence) |
| Clinical outcomes | |
| Pain crises | Decreased (low quality evidence) |
| Hospitalisations | Decreased (low quality evidence) |
| Blood transfusion therapy | Insufficient data |
| Acute chest syndrome | Insufficient data |
| Secondary stroke | Decreased (very low quality evidence) No effect (low quality evidence) |
| Prevention of end organ damage | |
| Spleen | No significant difference (low quality evidence) |
| Kidney | No significant difference (low quality evidence) |
| Brain (transcranial Doppler velocity) | Decreased (very low quality evidence) |
| Mortality | |
| Mortality | Decreased effect |
| Toxicity | |
| Neutropenia | Mild to moderate (moderate quality evidence) |
| Leg ulcers | Insufficient data |
| Thrombocytopenia | Insufficient data |
| Anaemia | Insufficient data |